antiviral

  1. Paddler

    A comprehensive analysis and resource to use CRISPR-Cas13 for broad-spectrum targeting of RNA viruses, 2021, Lin et al

    2021 paper Abstract A comprehensive analysis and resource to use CRISPR-Cas13 for broad-spectrum targeting of RNA viruses Xueqiu Lin 1,6, Yanxia Liu 1,6,7, Augustine Chemparathy 1,2,6, Tara Pande 3, Marie La Russa 1,7, Lei S Qi 1,4,5,7,8,∗ The coronavirus disease 2019 (COVID-19) pandemic caused...
  2. leokitten

    A novel PLpro inhibitor improves outcomes in a pre-clinical model of long COVID, 2025, Bader et al

    https://www.nature.com/articles/s41467-025-57905-4 Abstract The COVID-19 pandemic caused by the coronavirus SARS-CoV-2 has highlighted the vulnerability of a globally connected population to zoonotic viruses. The FDA-approved coronavirus antiviral Paxlovid targets the essential SARS-CoV-2 main...
  3. Hutan

    Longitudinal analysis and treatment of neuropsychiatric symptoms in post-acute sequelae of COVID-19, 2023, Liu et al

    2023 study https://link.springer.com/article/10.1007/s00415-023-11885-x Paywall Jennifer H. Yang, Lucas Patel, Jasmine Arora, Amanda Gooding, Ronald Ellis & Jennifer S. Graves San Diego team, University of California Abstract Background Persistent neuropsychiatric symptoms following acute...
  4. SNT Gatchaman

    [Preprint] TGF-β inhibitor SB431542 suppresses coronavirus replication through multistep inhibition, 2025, Verma et al.

    TGF-β inhibitor SB431542 suppresses coronavirus replication through multistep inhibition Assim Verma; Garvit Kumar; Nitin Khandelwal; Benjamin E Mayer; Jitender Rathee; Yogesh Chander; Alka Nokhwal; Shweta Dhanda; Ram Kumar; Himanshu Kamboj; Riyesh Thachamvally; Shalini Sharma; Naveen Kumar The...
  5. forestglip

    Analysis of risk factors for long COVID after mild COVID-19 during the Omicron wave in Japan, 2025,

    Analysis of risk factors for long COVID after mild COVID-19 during the Omicron wave in Japan Hotaka Namie, Takahiro Takazono, Rina Kawasaki, Hiroshi Yano, Yuya Ito, Nana Nakada, Tatsuro Hirayama, Masataka Yoshida, Kazuaki Takeda, Shotaro Ide, Shinnosuke Takemoto, Naoki Iwanaga, Masato Tashiro...
    • forestglip
    • Thread
    • age antiviral long covid neurological symptoms respiratory problems risk factors
    • Replies: 2
    • Forum: Long Covid research
  6. forestglip

    Preprint Anticoagulant vs. antiviral therapy, recovery and neurodamage in Long COVID: a real-world prospective cohort study, 2025, Jamoulle et al

    Anticoagulant vs. antiviral therapy, recovery and neurodamage in Long COVID: a real-world prospective cohort study Marc Jamoulle, Margaux Mignolet, Isabelle Meyts, Aurelie Ladang, Charles Nicaise, Johan Van Weyenbergh [Line breaks added] Abstract Recent estimates consider that Long COVID...
Back
Top